Peipei Xie
Key Laboratory Of Carcinogenesis And Translational Research
Beijing, 100142, China
Beijing, 100142, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.
Journal: Cancer metastasis reviews
Published: April 21, 2026
Erratum: Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation.
Journal: Molecular therapy. Oncology
Published: June 03, 2025
Peripheral TERT- positive leukocytes as a biomarker of the local and systemic immune failure in early-stage lung adenocarcinoma progression.
Journal: Molecular biomedicine
Published: March 26, 2025
Diagnostic and Predictive Value of CD133-Positive Circulating Tumor Cells as an Indicator of Pathological High-Risk Factors for Stage I Non-Small Cell Lung Cancer.
Journal: Cancer medicine
Published: November 26, 2024
Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation.
Journal: Molecular therapy. Oncology
Published: November 25, 2024
Postoperative continuous saline bladder irrigation reduces active urinary cancer cells: a prospective study in NMIBC.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: November 24, 2024
Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma.
Journal: Journal of hematology & oncology
Published: September 15, 2024
Concordance of HER2 status between primary tumor and circulating tumor cells in breast cancer.
Journal: Discover oncology
Published: August 24, 2024
Liquid biopsy: An arsenal for tumour screening and early diagnosis.
Journal: Cancer treatment reviews
Published: February 20, 2024
Circulating tumour cell isolation, analysis and clinical application.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: January 11, 2023
Showing 1-11 of 11
Last Updated: 09/26/2026